Endocrine Abstracts

Background: Androgen-deprivation therapy (ADT) is commonly used in the management of advanced prostate cancer. ADT can be achieved through bilateral orchidectomy, by administration of GnRH receptor agonists, or by using by the newer GnRH receptor antagonist Degarelix. The classical desired biochemical goal is to achieve a serum testosterone of <1.7 nmol/l.Case Presentation: A man with metastatic prostate cancer on androgen deprivation therapy and ser...